The latest market report published by Credence Research, Inc. “Oncology Biosimilars Market was valued at US$ 1,651.5 Mn in 2017 expanding at a CAGR of 28.3% from 2018 to 2026.
Credence Research lately added a new report titled “Oncology Biosimilars Market – Industry Size, Global Trends, Growth, Opportunities, Market Share and Market Forecast – 2017 to 2026” to its repository. This latest research study investigates the Oncology Biosimilars market through different segments primarily based on type, application and end-use, market participants, areas and presents country-level evaluation over the forecast period from 2017 to 2026.
Market Insights:
According to the U.S. Food and Drug Administration (FDA), biosimilar is a biological product that is highly similar to an existing, approved reference product and has no clinically meaningful differences. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. The number of biosimilar approvals soared in the United States as five of nine approved biosimilars across different disease conditions received U.S. FDA approval. Furthermore, U.S. witnessed the approvals of oncology biosimilars such as Amgen’s Mvasi (bevacizumab-awwb), a biosimilar to Genentech’s Avastin for the treatment of lung, colorectal, kidney, brain and cervical cancers; and Mylan’s Ogivri (trastuzumab-dkst), a biosimilar to Herceptin for treating breast cancer, gastric cancer, and gastrointestinal cancer. The USFDA is determined to increase biosimilar approvals, especially for cancer as cancer treatment imposes a high cost burden on patients. Although the prices of oncology biosimilars are less compared to biologics, the savings are not on the same scale as compared to generics and patented non-biological drugs. Savings of 20% – 30% compared to the reference biologic product have been observed in major markets such as Europe and North America, making biosimilars as a lucrative alternative.
Browse Here For Full Report Oncology Biosimilars Market – Growth, Future Prospects, and Competitive Landscape, 2017-2026 with ToC: https://www.credenceresearch.com/report/oncology-biosimilars-market
The report on the Oncology Biosimilars market provides in-depth analysis covering key regional trends, market dynamics, and presents the country-level market size of the Oncology Biosimilars industry. Some of the key elements considered during the course of research included product definition, product classification, enterprise structure, a number of participants in the Oncology Biosimilars, etc.
The report consists of market sizes and forecast for the period from 2017 to 2026, and compounded annual growth rate (CAGR%) measured for individual segments and regional markets, competitive landscape of main market players, vital analysis of market dynamics and profiling of key providers collaborating in the Oncology Biosimilars market.
Report Focus: The ‘Oncology Biosimilars – Global Trends, Estimates and Forecasts, 2017-2026’ reviews the latest developments in plastics industry with a perceptive to perceive the near-future growth prospects. The industry is a fragmented market with multiple participants, opens up numerous investment opportunities. The main investment focus is Oncology Biosimilars business. An in-depth analysis throughout the geographic regions gives strategic enterprise intelligence for the industry investments.
Get Sample Copy of this report: https://www.credenceresearch.com/sample-request/59205
The study offers profitable investment techniques for R&D organizations, manufacturing units, distributors, Contract Research Organizations (CROs) and many more in preferred locations.
The report primarily focuses on: Latest Market Trends,
- Region-wise Demand Factor
- Key Growth Areas
- Market Sizes
- Key Competitors Edge
- Investment Strategies
Estimates are primarily based on online surveys using customized questionnaires via our research team. Besides data from government databases, organization websites, press releases & published research reports are also used for estimates.
Geographic Coverage
- North America Oncology Biosimilars Market Revenue and Forecast
- Europe Oncology Biosimilars Market Revenue and Forecast
- Asia Pacific Oncology Biosimilars Market Revenue and Forecast
- Latin America Oncology Biosimilars Market Revenue and Forecast
- Middle East and Africa Oncology Biosimilars Market Revenue and Forecast
Leading Players:
- Amgen, Inc.
- Mylan N.V.
- Samsung Bioepis Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Celltrion Healthcare
- Novartis International AG
- Biocon Limited
- Biogen Idec
- Sandoz
- Reddy’s Laboratory
- Merck & Co.
- Shanghai Henlius Biotech, Inc.
- Biocad
Browse Here For Full Report with ToC: https://www.credenceresearch.com/report/oncology-biosimilars-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com
No comments:
Post a Comment